Diagnostic procedures for primary aldosteronism

LaboratoriumsMedizin

Volumn 33, Issue 4, 2009, Pages 202-209

  Pilz, Stefan ^a   Tomaschitz, Andreas ^a   Marz W ^a,b,c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c SYNLAB ACADEMY   (Germany)

Author keywords

Aldosterone; Arterial hypertension; Primary aldosteronism; Renin

Indexed keywords

ALDOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUDROCORTISONE; MINERALOCORTICOID ANTAGONIST; RENIN; SPIRONOLACTONE;

ADRENAL HYPERPLASIA; ADRENALECTOMY; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HIGH RISK PATIENT; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOPHYSIS ADENOMA; IDIOPATHIC DISEASE; KIDNEY DISEASE; PRIMARY HYPERALDOSTERONISM; REVIEW; SCREENING TEST;

EID: 67651171364     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2009.032     Document Type: Review

References (63)

1. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Man-tero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-81.
2. Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hyper-tens 2008;26:613-21.
3. Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2:198-208.
4. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8.
5. Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res 1997;20:85-90.
6. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, et al. Long-term renal outcomes in patients with primary aldosteronism. J Am Med Assoc 2006;295: 2638-45.
7. Catena C, Colussi GL, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008;168:80-5.
8. Strauch B, Petrak O, Zelinka T, Wichterle D, Holaj R, Kasalicky M, et al. Adrenalectomy improves arterial stiffness in primary aldosteronism. Am J Hypertens 2008;21:1086-92.
9. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955;45:3-17.
10. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci 2007;113:267-78.
11. Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 2008;29:133-54.
12. Mulatero P, Verhovez A, Morello F, Veglio F. Diagnosis and treatment of low-renin hypertension. Clin Endocrinol 2007; 67:324-34.
13. Warnock DG. Low-renin and nonmodulating essential hypertension. Hypertension 1999;34:395-7.
14. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashga-rian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab 2008;93:3117-23.
15. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141:1589-93.
16. McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73:952-7.
17. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003;21:2149-57.
18. Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endo-crinol Metab 2005;90:72-8.
19. Hirohara D, Nomura K, Okamoto T, Ujihara M, Takano K. Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low ren-in hypertensives. J Clin Endocrinol Metab 2001;86:4292-8.
20. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African Americans and white subjects with resistant hypertension. Am J Hypertens 2005;18:805-12.
21. Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M. Automated chemilumines-cence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassay with and without extraction steps. Clin Chem 2006;52:1749-55.
22. Turpeinen U, Hämäläinen E, Stenman UH. Determination of aldosterone in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;862:113-8.
23. Hartman D, Sagnella GA, Chesters CA, MacGregor GA. Direct renin and plasma renin activity assay compared. Clin Chem 2004;50:2159-61.
24. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldos-terone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005;16:86-91.
25. Piffanelli A, Morganti A, Mantero F, Cianetti A, Zucchelli GC, Giovannini G, et al. Supraregional interlaboratory quality-control survey for an immunoradiometric renin assay. Clin Chem 2001;47:2148-50.
26. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005;51:386-94.
27. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chian-dussi L, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40:897-902.
28. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol 2002;57:457-65.
29. Lamarre-Cliche M, de Champlain J, Lacourciere Y, Poirier L, Karas M, Larochelle P. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives. Am J Hypertens 2005;18:56-64.
30. Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003;88:2489-94.
31. Pilz S, Dobnig H, Fahrleitner-Pammer A, Polt G, Mä rz W. Vitamin D deficiency: a global health problem. J Lab Med 2008;32:200-8.
32. Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2006;91: 2618-23.
33. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, et al. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007;50:424-31.
34. Agharazii M, Douville P, Grose JH, Lebel M. Captopril versus salt loading in confirming primary aldosteronism. Hypertension 2001;37:1440-3.
35. Diederich S, Bidlingmaier M, Quinkler M, Reincke M. Diagnosis of primary aldosteronism. Med Klin 2007;102:16-22.
36. Westerdahl C, Bergenfelz A, Larsson J, Nerbrand C, Valdemarsson S, Wihl A, et al. Re-evaluation of the fludrocortisone test: duration, NaCl supplementation and cut-off limits for aldosterone. Scand J Clin Lab Invest 2009;69: 234-41.
37. Mulatero P, Bertello C, Garrone C, Rossato D, Mengozzi G, Verhovez A, et al. Captopril test can give misleading results in patients with suspect primary aldosteronism. Hypertension 2007;50:e26-7.
38. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, et al. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens 2007;25:1433-42.
39. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006;24:737-45.
40. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007;66:607-18.
41. Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 2005;12:149-59.
42. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004;136:1227-35.
43. Thompson GB, Young WF Jr. Adrenal incidentaloma. Curr Opin Oncol 2003;15:84-90.
44. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007;356:601-10.
45. Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol (Oxf) 2009;70:14-7.
46. Young WF Jr, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role of adrenal venous sampling in primary aldosteronism. Surgery 2004;136:1227-35.
47. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005;25(Suppl 1):143-58.
48. Stowasser M, Gordon RD. Primary aldosteronism - careful investigation is essential and rewarding. J Mol Cell Endocrinol 2004;217:33-9.
49. Auchus RJ, Michaelis C, Wians FH Jr, Dolmatch BL, Josephs SC, Trimmer CK, et al. Rapid cortisol assays improve the success rate of adrenal vein sampling for primary aldosteronism. Ann Surg 2009;249:318-21.
50. Ganguly A, Dowdy AJ, Luetscher JA, Melada GA. Anomalous postural response of plasma aldosterone concentrations in patients with aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 1973;36:401-4.
51. Phillips JL, McClellan MW, Pezzullo JC, Rayford W, Choyke PL, Berman AA, et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldos-terone-producing adrenal adenoma. J Clin Endocrinol Metab 2000;85:4526-33.
52. Espiner EA, Ross DG, Yandle TG, Richards AM, Hunt PJ. Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. J Clin Endocrinol Metab 2003;88:3637-44.
53. Volpe C, Enberg U, Sjögren A, Wahrenberg H, Jacobsson H, Tö rring O, et al. The role of adrenal scintigraphy in the preoperative management of primary aldosteronism. Scand J Surg 2008;97:248-53.
54. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995;207:565-71.
55. Gates LJ, Benjamin N, Haites NE, MacConnachie AA, McLay JS. Is random screening of value in detecting glu-cocorticoid-remediable aldosteronism within a hypertensive population? J Hum Hypertens 2001;15:173-6.
56. Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, et al. Further evidence for linkage of familial hyperaldoste-ronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens 2008;26: 1577-82.
57. Mourad JJ, Girerd X, Milliez P, Lopez-Sublet M, Lejeune S, Safar ME. Urinary aldosterone-to-active-renin ratio: a useful tool for predicting resolution of hypertension after adrena-lectomy in patients with aldosterone-producing adenomas. Am J Hypertens 2008;21:742-7.
58. Letavernier E, Peyrard S, Amar L, Zinzindohoue F, Fiquet B, Plouin PF. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 2008;26:1816-23.
59. Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldostero-nism. Br J Surg 2002;89:1587-93.
60. Born-Frontsberg E, Quinkler M. Conn's syndrome. Internist 2009;50:17-26.
61. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolac-tone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999;48:756-60.
62. Montori VM, Young WF. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin N Am 2002;31:619-32.
63. Pilz S, Tomaschitz A, Stepan V, Obermayer-Pietsch B, Fahrleitner-Pammer A, Schweighofer N, et al. Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. BMC Endocr Disord 2009;9:11.